CytoMed Therapeutics (GDTC) Stock Chart & Stock Price History $1.86 0.00 (0.00%) Closing price 08/8/2025 03:55 PM EasternExtended Trading$1.86 0.00 (0.00%) As of 08/8/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsSEC FilingsShort InterestTrendsBuy This Stock CytoMed Therapeutics Stock Price Performance The CytoMed Therapeutics (GDTC) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 3.91%, with a year-to-date return of -45.29%. In the past month, the stock has decreased 15.45%, reflecting recent market activity. As of the latest close, CytoMed Therapeutics traded at $1.86 with a market cap of $0.00 and volume of 3,266 shares. Receive GDTC Stock News and Ratings via EmailSign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+1.36%1 Month Performance-15.45%3 Month Performance-16.22%Year-To-Date Performance-45.29%1 Year Performance+3.91% GDTC Stock Chart for Sunday, August, 10, 2025 GDTC Chart by TradingView CytoMed Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/08/2025$1.85$1.86+0.54%$1.88$1.853,266 shs$0.0008/07/2025$1.85$1.85$1.86$1.86326 shs$20.24 million08/06/2025$1.84$1.85+0.82%$1.86$1.812,962 shs$0.0008/05/2025$1.86$1.84-1.34%$1.85$1.7912,681 shs$0.0008/04/2025$1.83$1.86+1.64%$1.89$1.836,126 shs$0.0008/01/2025$1.90$1.83-3.43%$1.92$1.834,060 shs$0.0007/31/2025$1.90$1.90$1.88$1.835,219 shs$20.73 million07/30/2025$1.91$1.90-0.73%$1.92$1.7716,700 shs$0.0007/29/2025$1.90$1.91+0.47%$1.95$1.898,702 shs$0.0007/28/2025$1.87$1.90+1.88%$1.90$1.865,212 shs$20.79 million Get the Latest News and Ratings for GDTC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 07/25/2025$1.90$1.87-1.84%$1.91$1.857,038 shs$20.40 million07/24/2025$1.89$1.90+0.53%$1.97$1.8989,635 shs$0.0007/23/2025$2.02$1.89-6.44%$2.04$1.7555,330 shs$0.0007/22/2025$2.04$2.02-0.98%$2.09$2.007,224 shs$22.10 million07/21/2025$2.04$2.04$2.26$2.0064,849 shs$0.0007/18/2025$2.05$2.04-0.49%$2.02$1.969,492 shs$0.0007/17/2025$2.07$2.05-0.97%$2.05$2.0016,528 shs$0.0007/16/2025$2.04$2.07+1.47%$2.11$2.029,115 shs$22.65 million07/15/2025$2.21$2.04-7.69%$2.15$2.0125,607 shs$0.0007/14/2025$2.18$2.21+1.56%$2.22$2.127,573 shs$0.0007/11/2025$2.20$2.18-1.09%$2.21$2.211,505 shs$0.0007/10/2025$2.25$2.20-2.22%$2.35$2.1613,140 shs$0.0007/09/2025$2.31$2.25-2.60%$2.27$2.097,280 shs$24.62 million Related Companies ATNFW Stock Chart LBPSW Stock Chart AEHAW Stock Chart AIMDW Stock Chart ALVOW Stock Chart ACABW Stock Chart BFRIW Stock Chart BTMDW Stock Chart BCTXW Stock Chart CELUW Stock Chart Receive GDTC Stock News and Ratings via EmailSign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:GDTC) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredChina's 500 Million Year AdvantageThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
